Greener Pastures? Long-Time Pfizer China GM Starts New Era
Executive Summary
15 year-serving Pfizer China GM Wu Xiaobing and AstraZeneca China's Senior VP for biologics Shoubai Chao are the latest to jump on board China's booming biotech boat, are there more to come?
You may also be interested in...
Asia Executives To Watch: Moves At ZAI, Daiichi Sankyo And Others
The coming of June has brought new executives at Daiichi Sankyo, UCB, ViiV in Japan and ZAI Lab in China.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.